Esperion Therapeutics (ESPR) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue rose 186% year-over-year to $73.8 million, with US net product revenue up 39% to $28.3 million, driven by expanded labels and payer access for Nexletol and Nexlizet.

• Monetized European royalty stream for $304.7 million, using proceeds to pay off and terminate the Oberland Capital facility, significantly improving liquidity and financial flexibility.

• Expanded payer access, with over 114 million lives covered under updated UM criteria, 92% preferred commercial coverage, and Medicare preferred coverage exceeding 50%.

• International launches and regulatory progress included label expansions in Europe, Thailand, Macau, and positive Phase 3 results in Japan, with filings pending in Japan, Canada, Australia, and Israel.

• Published new clinical data supporting cardiovascular risk reduction benefits of bempedoic acid, comparable to statins.

Financial highlights

• Q2 2024 total revenue: $73.8 million (up 186% year-over-year); US net product revenue: $28.3 million (up 39% year-over-year); collaboration revenue: $45.5 million (up 727% year-over-year).

• R&D expenses decreased 48% to $11.5 million, while SG&A expenses rose 30% to $44.2 million.

• One-time loss on extinguishment of debt was $53.2 million; net loss for the quarter was $61.9 million, compared to $49.9 million in Q2 2023.

• Cash and cash equivalents stood at $189.3 million as of June 30, 2024, up from $82.2 million at year-end 2023.

• Operating expenses for Q2 2024: $71.3 million (up from $62.8 million in Q2 2023).

Outlook and guidance

• Full-year 2024 operating expense guidance reiterated at $225 million–$245 million, including $20 million in non-cash stock compensation.

• Expect continued growth in product sales as payer access and physician confidence increase.

• New Drug Applications in Canada, Australia, and Israel on track for submission by year-end; Japan NDA filing expected in H2 2024.

• Anticipate DSE to complete tech transfer and begin independent production in Europe by end of 2025, reducing COGS.

• Management expects continued operating losses as commercialization and R&D activities persist.